SCHEMBL12840774

SCHEMBL12840774

CC(=O)Cc1ccc(NC(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
RXFP1 Q9HBX9 1/20 0.51
TDP1 Q9NUW8 4/20 0.43
PLAU P00749 1/20 0.42
ALDH1A1 P00352 4/20 0.42
TSHR P16473 4/20 0.42
CYP3A4 P08684 2/20 0.42
THRB P10828 2/20 0.42
ALOX15 P16050 2/20 0.42
HSD17B10 Q99714 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 2/20 0.42
ALOX12 P18054 1/20 0.42
RECQL P46063 1/20 0.42
ATM Q13315 1/20 0.42
KDM4E B2RXH2 1/20 0.39
NLRP3 Q96P20 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 1/20 0.39
GAA P10253 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9911354 0.85 MEN1 (0.50) POLBRXFP1TDP1PLAUALDH1A1
SCHEMBL12667382 0.83 RXFP1 (0.46) POLBRXFP1TDP1PLAUALDH1A1
SCHEMBL13282267 0.81 ALDH1A1 (0.53) POLBRXFP1TDP1ALDH1A1TSHR
SCHEMBL24920157 0.81 RXFP1 (0.51) POLBRXFP1TDP1PLAUALDH1A1
SCHEMBL16981017 0.80 RXFP1 (0.44) RXFP1TDP1PLAUALDH1A1TSHR
SCHEMBL7148287 0.80 SMN1; SMN2 (0.59) POLBTDP1ALDH1A1TSHRCYP3A4
SCHEMBL12674309 0.79 NEK2 (0.43) POLBRXFP1TDP1ALDH1A1TSHR
SCHEMBL8403545 0.78 POLB (0.61) POLBALDH1A1TSHRHSD17B10LMNA
SCHEMBL7517494 0.78 KMT2A (0.54) POLBRXFP1ALDH1A1RECQLKMT2A
SCHEMBL10131962 0.78 POLB (0.48) POLBALDH1A1TSHRCYP3A4THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-20110077381-A1 NOVEL NPR-B AGONISTS ALCON RESEARCH, LTD. (US) 2011-03-31 US disclosed
US-20100136034-A1 NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077381-A1 NOVEL NPR-B AGONISTS NPR1, NPR3, NPBWR1 POLB 4268/4885RXFP1 9/4885TDP1 3361/4885
US-20100136034-A1 NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS TNFRSF1A, TNFRSF9, CD40 POLB 3362/4885RXFP1 824/4885TDP1 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.